Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (SHA:600332)
China · Delayed Price · Currency is CNY 22.97
-0.30 (-1.29%)
Mar 26, 2026, 11:30 AM CST
SHA:600332 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 77,413 | 74,779 | 75,275 | 70,550 | 68,758 |
Other Revenue | 243.57 | 214.3 | 240.53 | 237.96 | 256.1 |
| 77,656 | 74,993 | 75,515 | 70,788 | 69,014 | |
Revenue Growth (YoY) | 3.55% | -0.69% | 6.68% | 2.57% | 11.90% |
Cost of Revenue | 65,134 | 62,518 | 61,373 | 57,548 | 55,825 |
Gross Profit | 12,522 | 12,475 | 14,143 | 13,240 | 13,189 |
Selling, General & Admin | 8,315 | 8,003 | 8,484 | 8,062 | 7,955 |
Research & Development | 661.63 | 763.77 | 782.14 | 819.45 | 874.72 |
Other Operating Expenses | 241.03 | -46.38 | 6.38 | -182.76 | 294.43 |
Operating Expenses | 9,319 | 8,779 | 9,346 | 8,753 | 9,219 |
Operating Income | 3,203 | 3,696 | 4,796 | 4,487 | 3,970 |
Interest Expense | -401.51 | -418.15 | -446.19 | -434.41 | -417.83 |
Interest & Investment Income | 610.46 | 698.33 | 751.18 | 1,048 | 757.45 |
Currency Exchange Gain (Loss) | 3.87 | -3.15 | 3.32 | -11.12 | 8.67 |
Other Non Operating Income (Expenses) | -41.69 | -27.94 | -45.01 | -41.12 | -94.44 |
EBT Excluding Unusual Items | 3,374 | 3,945 | 5,060 | 5,048 | 4,224 |
Gain (Loss) on Sale of Investments | -18.7 | -361.01 | 38.64 | -3.59 | 196.88 |
Gain (Loss) on Sale of Assets | 107.74 | 11.12 | 12.03 | 0.69 | 0.69 |
Asset Writedown | -3.92 | -2.93 | 0.42 | -7.06 | -3.08 |
Legal Settlements | - | - | - | - | -24.82 |
Other Unusual Items | 231.06 | 15.71 | -0.36 | 4.76 | 329.44 |
Pretax Income | 3,690 | 3,608 | 5,110 | 5,043 | 4,723 |
Income Tax Expense | 629.22 | 606.85 | 851.17 | 789.87 | 754.09 |
Earnings From Continuing Operations | 3,061 | 3,001 | 4,259 | 4,253 | 3,969 |
Minority Interest in Earnings | -77.6 | -165.24 | -203.65 | -286.85 | -249.11 |
Net Income | 2,983 | 2,835 | 4,056 | 3,967 | 3,720 |
Net Income to Common | 2,983 | 2,835 | 4,056 | 3,967 | 3,720 |
Net Income Growth | 5.21% | -30.09% | 2.25% | 6.63% | 27.60% |
Shares Outstanding (Basic) | 1,626 | 1,626 | 1,626 | 1,626 | 1,626 |
Shares Outstanding (Diluted) | 1,626 | 1,626 | 1,626 | 1,626 | 1,626 |
Shares Change (YoY) | -0.01% | 0.02% | -0.02% | - | - |
EPS (Basic) | 1.83 | 1.74 | 2.50 | 2.44 | 2.29 |
EPS (Diluted) | 1.83 | 1.74 | 2.50 | 2.44 | 2.29 |
EPS Growth | 5.22% | -30.10% | 2.27% | 6.63% | 27.61% |
Free Cash Flow | -1,472 | 2,314 | 2,475 | 5,615 | 4,419 |
Free Cash Flow Per Share | -0.91 | 1.42 | 1.52 | 3.45 | 2.72 |
Dividend Per Share | 0.850 | 0.800 | 0.749 | 0.732 | 0.687 |
Dividend Growth | 6.25% | 6.81% | 2.32% | 6.55% | 27.69% |
Gross Margin | 16.13% | 16.63% | 18.73% | 18.70% | 19.11% |
Operating Margin | 4.12% | 4.93% | 6.35% | 6.34% | 5.75% |
Profit Margin | 3.84% | 3.78% | 5.37% | 5.60% | 5.39% |
Free Cash Flow Margin | -1.90% | 3.09% | 3.28% | 7.93% | 6.40% |
EBITDA | 3,841 | 4,330 | 5,462 | 5,002 | 4,390 |
EBITDA Margin | 4.95% | 5.77% | 7.23% | 7.07% | 6.36% |
D&A For EBITDA | 638.7 | 634.73 | 665.32 | 514.44 | 419.91 |
EBIT | 3,203 | 3,696 | 4,796 | 4,487 | 3,970 |
EBIT Margin | 4.12% | 4.93% | 6.35% | 6.34% | 5.75% |
Effective Tax Rate | 17.05% | 16.82% | 16.66% | 15.66% | 15.97% |
Revenue as Reported | 77,656 | 74,993 | - | - | - |
Advertising Expenses | 1,017 | 930.48 | 1,082 | 960.69 | 1,054 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.